Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Oxytrol (oxybutynin) for the Treatment of Overactive Bladder (OAB) in Women

Drug Name (Brand / Generic)

Oxytrol / oxybutynin

Company / Licensee

Merck / Watson Pharmaceuticals (Actavis)

Therapy Class

Anticholinergic agent

Current Indication

Overactive Bladder (OAB)

Market Sector

Nephrology

Development Status

Approved in the US, Europe and Canada
Expand
Close
Close
Close

Go Top